Inovio Pharmaceuticals, Inc. (INO): Morton Collins , director of Inovio Pharmaceuticals, Inc. purchased 10,000 shares on Jun 28, 2016. The Insider buying transaction was reported by the company on Jun 29, 2016 to the Securities and Exchange Commission. The shares were purchased at $9.13 per share for a total value of $91,309.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 18, 2016, Simon X Benito (director) sold 6,250 shares at $10.37 per share price.On Apr 18, 2016, Morton Collins (director) purchased 68,400 shares at $9.49 per share price.Also, On Sep 30, 2015, Niranjan Sardesai (COO) purchased 4,000 shares at $5.50 per share price.On Apr 13, 2015, Angel Cabrera (director) purchased 8,000 shares at $9.53 per share price.
Shares of Inovio Pharmaceuticals Inc (INO) ended Monday, Jun 27, 2016 session in red amid volatile trading. The shares closed down -0.88 points or -9.60% at $8.29 with 29,18,634 shares getting traded. Post opening the session at $9.03, the shares hit an intraday low of $8.245 and an intraday high of $9.05 and the price vacillated in this range throughout the day. The company has a market cap of $606 M and the number of outstanding shares has been calculated to be 7,30,97,059 shares. The 52-week high of Inovio Pharmaceuticals Inc is $11.69 and the 52-week low is $4.5.
Inovio Pharmaceuticals Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31 2014 Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers prostate cancer breast/lung/pancreatic cancer hepatitis C virus (HCV) hepatitis B virus (HBV) HIV influenza and Ebola. With its immunotherapy platform consisting of SynCon products as well as its CELLECTRA electroporation delivery technology Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovio’s immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.